Clinical trials: Exposure, Environmental
Ragweed Allergy, Rhinoconjunctivitis
ToleroMune Ragweed Follow up Study
Ragweed is the primary cause of autumn allergies. The ragweed season begins in mid-August. In the third National Health and Nutrition Examination Surveys54.3% of the population had positive test responses to one or more…
- Trial name
- NCT01448603
- Testing
- ToleroMune Ragweed
- Where
- Canada
- Volunteers
- 109 people
- Sponsor
- Circassia Limited
Seasonal Allergic Conjunctivitis to Ragweed
A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.
The purpose of this study is to test if olopatadine punctal plugs can reduce the symptoms (itching) of allergic conjunctivitis to ragweed in an Environmental Exposure Chamber model.
- Trial name
- NCT01287338
- Testing
- Olopatadine
- Where
- Canada
- Volunteers
- 143 people
- Sponsor
- Mati Therapeutics Inc.
Allergic Rhinitis, Rhinoconjunctivitis
Red Maple Trials Cat Allergen Natural Exposure Chamber Validation in Cat-allergic Subjects
To assess the reproducibility of the allergic response in the cat allergic subjects, measured as the change from baseline of the Total Nasal Symptom Score (TNSS) on the two challenge days.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Exposure
- Trial name
- NEC (NCT03414801)
- Testing
- Allergen Exposure
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Red Maple Trials Inc.
Allergic Rhinoconjunctivitis
A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber
The trial is a phase II, randomised, parallel-group, double-blind, placebo-controlled multi-site trial conducted in Canada. Before the start of treatment, the subjects will undergo baseline birch and oak Environmental Exposure…
- Trial name
- NCT02481856
- Testing
- SQ tree SLIT-tablet
- Where
- Canada
- Volunteers
- 219 people
- Sponsor
- ALK-Abelló A/S
Asthma
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction…
- Trial name
- AERO (NCT00495612)
- Testing
- Omalizumab
- Volunteers
- 69 people
- Sponsor
- Genentech, Inc.
Dry Eye Syndromes
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
This study evaluates the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally (active) compared with the same device applied extranasally (control) relating to symptoms of dry eye exacerbated by…
- Trial name
- NCT02910713
- Testing
- Intranasal Tear Neurostimulator
- Where
- 3 sites in United States
- Volunteers
- 185 people
- Sponsor
- Allergan
Seasonal Allergic Rhinitis
Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)
This study is to evaluate the effectiveness of a new drug on congestion in subjects with seasonal allergic rhinitis. This effect will be compared to placebo and to the decongestant, pseudoephedrine.
- Trial name
- NCT00673062
- Testing
- SCH 900538, Pseudoephedrine
- Volunteers
- 265 people
- Sponsor
- Merck Sharp & Dohme LLC
Cat Allergy
Cat-PAD Exposure Chamber Study
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01033344
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 210 people
- Sponsor
- Circassia Limited
Birch Pollen Allergy
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of three ascending dosing schemes of DM-101-PX in birch pollen allergic adults.
- Trial name
- NCT06037148
- Testing
- DM-101PX
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Desentum Oy
Cat Allergy
Exposure Chamber Trial With Cat Immunotherapy
The main purpose of this trial is to investigate if any of three different doses of cat hair immunotherapy is safe for treatment of cat allergic patients.
- Trial name
- NCT00987909
- Testing
- Specific allergen immunotherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- ALK-Abelló A/S
Grass Pollen Induced Allergic Rhinoconjunctivitis
Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber
The clinical trial will investigate the efficacy of Avanz Phleum pratense in the treatment of rhinitis in an environmental challenge chamber.
- Trial name
- AV-G-03 (NCT02166268)
- Testing
- AVANZ Phleum pratense 15,000 SQ+
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- ALK-Abelló A/S
Cat Allergy, Rhinoconjunctivitis
An Optional Two Year Follow Up Study to Study CP005A
Cat allergy is an increasingly prevalent condition affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01604018
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Circassia Limited
Skin Cancer, Occupational Exposure
Virtual Sun Safe Workplaces Ph II (SSW Works)
Americans who work outdoors are exposed to an extreme amount of solar ultraviolet radiation over a lifetime that substantially increases their risk for developing skin cancer.
- Trial name
- NCT05774600
- Testing
- SSW Works, Minimal Information Control
- Where
- United States
- Volunteers
- 543 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Atopic Dermatitis
The Effect of Nature-based Exposure on the Immune System and Skin Health of Atopic Dermatitis Patients.
The purpose of the study is to explore the effect of nature-based exposure on immunological biomarkers and the condition and symptoms of atopic skin.
- Trial name
- NCT06129136
- Testing
- Nature-based exposure by biodiversity component in lotion.
- Where
- Finland
- Volunteers
- 142 people
- Sponsor
- Uute Scientific Oy
Eye Manifestations
Comparison of Ectoin® Containing Eye Drops and Ectoin® Containing Eye Spray With the Eye Spray Tears Again®
This study aims to gain knowledge on the duration of symptom relief of environmental disorders of the eye as might be present in allergy sufferers after allergen exposure following application of the study products.
- Trial name
- NCT04021225
- Testing
- Ectoin® Allergy Eye Drops 2%, Ectoin® Eye Spray Colloidal, Tears Again® eye spray
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Bitop AG
Rhinitis, Allergic
A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure
The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering…
- Trial name
- NCT03443843
- Testing
- loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D), Fluticasone Propionate
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- Bayer
Allergic Rhinitis Due to Allergens, Rhinitis Allergic
Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis
The purpose of this trial is to see how well an experimental nasal spray, called INI-2004, works for those with allergy symptoms to ragweed.
- Conditions
- Allergic Rhinitis Due to Allergens, Rhinitis Allergic, Allergic Rhinitis
- Trial name
- NCT07556393
- Testing
- INI-2004
- Where
- Canada
- Volunteers
- 78 people
- Sponsor
- Inimmune Corporation
Allergic Conjunctivitis
A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)
This is a Phase II Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel, Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis…
- Trial name
- NCT02082899
- Testing
- Active Comparator EBI-005 5 mg/mL
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Eleven Biotherapeutics
Rhinitis, Allergic
A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen
The purpose of the study is to assess the efficacy comparability of cetirizine and levocetirizine, by comparing the effects of single intake of the two drugs to placebo in reducing symptoms of seasonal allergic rhinitis (SAR) in…
- Conditions
- Rhinitis, Allergic, Seasonal
- Trial name
- NCT00291642
- Testing
- Levocetirizine drops, Levocetirizine tablets
- Where
- Canada
- Volunteers
- 551 people
- Sponsor
- UCB Pharma
Seasonal Allergic Rhinitis
Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)
A single-center, double-blind, placebo-controlled study of FDC olopatadine hydrochloride and mometasone furoate nasal spray (Molo; also referred as GSP 301) was conducted in subjects with seasonal allergic rhinitis.
- Trial name
- GSP 301- PoC (NCT03444506)
- Testing
- Molo 1 (also referred as GSP 301-2 NS), Molo 2 (also referred as GSP 301-1 NS), DYMISTA nasal spray
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India